These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 19035879)
1. Role of adenosine antagonism in the cardiorenal syndrome. Dohadwala MM; Givertz MM Cardiovasc Ther; 2008; 26(4):276-86. PubMed ID: 19035879 [TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM; J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315 [TBL] [Abstract][Full Text] [Related]
3. Adenosine1 receptor antagonism: a new therapeutic approach for the treatment of decompensated heart failure. Shah RH; Frishman WH Cardiol Rev; 2009; 17(3):125-31. PubMed ID: 19384086 [TBL] [Abstract][Full Text] [Related]
4. Acute decompensated heart failure and the cardiorenal syndrome. Liang KV; Williams AW; Greene EL; Redfield MM Crit Care Med; 2008 Jan; 36(1 Suppl):S75-88. PubMed ID: 18158481 [TBL] [Abstract][Full Text] [Related]
5. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947 [TBL] [Abstract][Full Text] [Related]
6. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351 [TBL] [Abstract][Full Text] [Related]
13. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC; J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154 [TBL] [Abstract][Full Text] [Related]
14. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. Greenberg B; Thomas I; Banish D; Goldman S; Havranek E; Massie BM; Zhu Y; Ticho B; Abraham WT J Am Coll Cardiol; 2007 Aug; 50(7):600-6. PubMed ID: 17692744 [TBL] [Abstract][Full Text] [Related]
15. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM; J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433 [TBL] [Abstract][Full Text] [Related]
16. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Slawsky MT; Givertz MM Expert Opin Pharmacother; 2009 Feb; 10(2):311-22. PubMed ID: 19236201 [TBL] [Abstract][Full Text] [Related]